{
  "id": "b77ec772-3114-4146-ad6f-5f7fd64668b0",
  "title": "DBV stock rallies post-market on FDA Viaskin update",
  "link": "https://seekingalpha.com/news/4385769-dbv-stock-rallies-post-market-on-fda-viaskin-update?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Wed, 11 Dec 2024 18:54:02 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "dbvt"
  ],
  "byline": "Val Brickates Kennedy",
  "length": 398,
  "excerpt": "DBV Technologies (DBVT) stock shot up 29% in post-market after the company said it has aligned with the FDA on an accelerated approval pathway for its peanut allergy patch Viaskin.",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Healthcare Professor25/iStock via Getty Images DBV Technologies (NASDAQ:DBVT) stock shot up 29% in post-market trading Wednesday after the company said it has aligned with the FDA on an accelerated approval pathway for its peanut allergy patch Viaskin for children aged one to three years. The Recommended For YouAbout DBVT StockCompare to PeersRelated StocksDBVT-Trending AnalysisTrending News",
  "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w750",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"content\"\u003e\u003carticle data-test-id=\"grid-container\"\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"grid-col-main\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003cdiv data-test-id=\"quick-links\"\u003e\u003cul\u003e\u003cli\u003e\u003ca data-test-id=\"theme-links-item\" href=\"https://seekingalpha.com/market-news/healthcare#source=section%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Ahealthcare%7Cfirst_level_url%3Anews\"\u003e\u003cspan\u003e\u003cspan\u003eHealthcare\u003c/span\u003e\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/header\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cfigure data-type=\"getty-image\"\u003e \u003cpicture\u003e \u003cimg src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w750\" alt=\"Peanut allergy\" data-id=\"475732628\" data-type=\"getty-image\" width=\"4704px\" height=\"3136px\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/475732628/image_475732628.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\"/\u003e \u003c/picture\u003e \u003cfigcaption data-type=\"getty-image\"\u003e\u003cp\u003eProfessor25/iStock via Getty Images\u003c/p\u003e\u003c/figcaption\u003e \u003c/figure\u003e\u003cul\u003e \u003cli\u003eDBV Technologies (\u003cspan\u003eNASDAQ:\u003ca href=\"https://seekingalpha.com/symbol/DBVT\" title=\"DBV Technologies S.A.\"\u003eDBVT\u003c/a\u003e\u003c/span\u003e) stock shot up 29% in post-market trading Wednesday after the company said it has aligned with the FDA on an accelerated approval pathway for its peanut allergy patch Viaskin for children aged one to three years.\u003c/li\u003e \u003cli\u003eThe\u003c/li\u003e \u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"recommended-section\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch4 data-test-id=\"recommended-for-you-card-title\"\u003eRecommended For You\u003c/h4\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"right-rail\"\u003e\u003cdiv data-test-id=\"about-symbol-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"about-symbol-card-title\"\u003eAbout DBVT Stock\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"about-symbol-chart\"\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003c/tbody\u003e\u003c/table\u003e\u003cul\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003cli\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003cp\u003e\u003ca data-test-id=\"about-symbol-footer-link\" href=\"https://seekingalpha.com/comparison/new/MCUyQ2RidnQ=#source=first_level_url%3Anews%7Csection%3Aabout%7Cbutton%3Acompare\" target=\"_blank\"\u003e\u003cspan\u003eCompare to Peers\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"suggested-symbols-card\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch3 data-test-id=\"suggested-symbols-card-title\"\u003eRelated Stocks\u003c/h3\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv\u003e\u003ctable data-test-id=\"table\"\u003e\u003cthead data-test-id=\"table-header\"\u003e\u003c/thead\u003e\u003ctbody data-test-id=\"table-body\"\u003e\u003ctr\u003e\u003ctd\u003e\u003ca data-test-id=\"dbvt-link\" href=\"https://seekingalpha.com/symbol/DBVT#source=first_level_url%3Anews%7Csection%3Aright_rail%7Csection_asset%3Arelated_stocks%7Csymbol%3Adbvt%7Cline%3A1\"\u003eDBVT\u003c/a\u003e\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/table\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-articles-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-articles-cards-title\" id=\"trending-articles-cards-container\"\u003eTrending Analysis\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"trending-news-cards-container\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-news-cards-title\" id=\"trending-news-cards-container\"\u003eTrending News\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003c/article\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "Less than 1 min",
  "publishedTime": "2024-12-11T23:54:02Z",
  "modifiedTime": "2024-12-11T18:54:03-05:00"
}
